DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
The Autosomal Dominant Polycystic Kidney Disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM Autosomal Dominant Polycystic Kidney Disease market size from 2019–2032. The report also covers current Autosomal Dominant Polycystic Kidney Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market:
Got queries? Click here to know more about the Autosomal Dominant Polycystic Kidney Disease Market Landscape
Autosomal Dominant Polycystic Kidney Disease Overview
Autosomal Dominant Polycystic Kidney Disease is a genetic disorder that causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure.
Autosomal Dominant Polycystic Kidney Disease may lead to the development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRT). The most common extra-renal manifestation is a polycystic liver disease (PLD), which is more common in women than in men.The most common symptoms are kidney cysts, pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, and brain aneurysms.
Autosomal Dominant Polycystic Kidney Disease Epidemiological Insight:
Autosomal Dominant Polycystic Kidney Disease Epidemiological Segmentation
Autosomal Dominant Polycystic Kidney Disease Market Outlook
Autosomal dominant polycystic kidney disease also called “adult PKD” is the most common inherited kidney disorder characterized by the growth of cysts in the kidneys, which eventually leads to kidney failure. A monogenetic disorder, Autosomal Dominant Polycystic Kidney Disease is caused by mutations in either the PKD1 gene found on chromosome 16 or the PKD2 gene found on chromosome 4. Mutations in PKD1 are more common and account for about 85% of all Autosomal Dominant Polycystic Kidney Disease cases. These genes encode for proteins of the polycystin signaling complex, which regulates different signals, including 3’,5’-cyclic adenosine monophosphate (cAMP), mammalian target of rapamycin (mTOR), and epidermal growth factor receptor pathways.
There is currently no effective curative treatment for Autosomal Dominant Polycystic Kidney Disease, and most efforts are aimed at mitigating the complications and progression or reducing cyst growth and delaying the eventual progression to kidney failure. Tolvaptan (Jynarque/Jinarc/Samsca), developed by Otsuka Pharmaceuticals, is the only approved drug available globally for treating Autosomal Dominant Polycystic Kidney Disease in adults. It inhibits vasopressin receptors in the kidneys and retards kidney function decline by reducing adenylate cyclase activity in adults at risk of rapidly progressing Autosomal Dominant Polycystic Kidney Disease.
Learn more by requesting for sample @Autosomal Dominant Polycystic Kidney Disease Market Landscape
Autosomal Dominant Polycystic Kidney Disease Key Companies
Autosomal Dominant Polycystic Kidney Disease Key Therapies
Table of Contents
Click here to read more about Autosomal Dominant Polycystic Kidney Disease Market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com